Colistin regained global interest as a consequence of the rising prevalence of multidrug-
resistant Gram-negative Enterobacteriaceae. In parallel, colistin-resistant bacteria emerged …

Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is
challenging, and some of the few active drugs are not available in many countries. For …

Background The β-lactamase inhibitor relebactam can restore imipenem activity against
imipenem-nonsusceptible gram-negative pathogens. We evaluated imipenem/relebactam …

Polymyxins are well-established antibiotics that have recently regained significant interest
as a consequence of the increasing incidence of infections due to multidrug-resistant Gram …

Colistin is an effective antibiotic for treatment of most multidrug-resistant Gram-negative
bacteria. It is used currently as a last-line drug for infections due to severe Gram-negative …

The rising prevalence of multidrug-resistant bacteria is an urgent health crisis that can only
be countered through renewed investment in the discovery and development of antibiotics …

Background: Infections caused by multi-drug-resistant Gram-negative bacteria, particularly
Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae, that …

In the face of the alarming rise in global antimicrobial resistance, only a handful of novel
antibiotics have been developed in recent decades, necessitating innovations in therapeutic …

Objectives Alterations in the PhoPQ two-component regulatory system may be associated
with colistin resistance in Klebsiella pneumoniae. MgrB is a small transmembrane protein …

Our objective was to examine the evidence of in vitro synergy of polymyxin-carbapenem
combination therapy against Gram-negative bacteria (GNB). A systematic review and meta …